Rienso: hypersensitivity warnings strengthened

Takeda has issued a letter to healthcare professionals about the risk of serious hypersensitivity reactions associated with the use of its injectable colloidal iron-carbohydrate complex, ferumoxytol (Rienso).

Rienso (ferumoxytol) is indicated for the treatment of iron-deficiency anaemia in chronic kidney disease. | SCIENCE PHOTO LIBRARY
Rienso (ferumoxytol) is indicated for the treatment of iron-deficiency anaemia in chronic kidney disease. | SCIENCE PHOTO LIBRARY

In agreement with the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), the following changes have been made to the prescribing information for Rienso to mitigate the risk of serious hypersensitivity reactions:

  • Rienso is now contraindicated in patients with any history of drug allergy, including previous hypersensitivity to other parenteral iron products
  • Rienso should only be administered as an intravenous infusion after dilution in 50–250ml of sterile 0.9% NaCl or sterile 5% glucose and must be given over at least 15 minutes
  • Patients should be monitored for signs and symptoms of hypersensitivity reactions, including blood pressure and pulse rate, during and for at least 30 minutes after completion of the infusion
  • Patients should be advised to seek urgent medical attention if they start to feel unwell
  • Rienso must only be administered by trained staff in an environment where resuscitation facilities are available

View Rienso drug record

Further information: Takeda

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...